Dominari (NASDAQ:DOMH) Issues Earnings Results, Misses Estimates By $9.26 EPS

Dominari (NASDAQ:DOMH) posted its quarterly earnings results on Tuesday. The company reported ($9.43) EPS for the quarter, missing the consensus estimate of ($0.17) by ($9.26), FiscalAI reports. Dominari had a negative return on equity of 50.80% and a net margin of 110.86%.

Dominari Stock Performance

Shares of NASDAQ DOMH opened at $2.85 on Tuesday. The stock’s 50-day simple moving average is $3.41 and its 200-day simple moving average is $4.58. The firm has a market capitalization of $46.23 million, a PE ratio of 0.51 and a beta of 0.83. Dominari has a fifty-two week low of $2.75 and a fifty-two week high of $8.40.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, January 12th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Dominari presently has an average rating of “Sell”.

Institutional Trading of Dominari

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new stake in shares of Dominari during the 4th quarter worth approximately $50,000. Price T Rowe Associates Inc. MD acquired a new stake in Dominari during the 4th quarter worth $96,000. Oxford Asset Management LLP acquired a new stake in Dominari during the 4th quarter worth $120,000. Jane Street Group LLC purchased a new stake in Dominari in the second quarter valued at $158,000. Finally, Millennium Management LLC acquired a new position in Dominari in the third quarter valued at $213,000. Institutional investors and hedge funds own 42.48% of the company’s stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.